Top Markets
Coin of the day
Immunotech Laboratories, Inc. Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc.

IMMB
Rank in Stocks #40594
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins... Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Share Price
$0.0002
Last synced: 2026-08-12
Market Cap
$114.99K
Change (1 day)
0.00%
Change (1 year)
100.00%
Country
US
Trade Immunotech Laboratories, Inc. (IMMB)

Category

P/S ratio for Immunotech Laboratories, Inc. (IMMB)
P/S ratio as of 2026 TTM: 0
According to Immunotech Laboratories, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Immunotech Laboratories, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE